Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 19
Tirzepatide in SURMOUNT-OSA
SURMOUNT-OSA found large AHI reductions with tirzepatide, alongside weight and blood-pressure changes, but no cardiovascular-event result.
Why Kidney Drug Programs Fail
A 2026 review uses failed and constrained diabetic kidney disease programs to examine target validation, endpoints and safety limits.
FLOW Safety Across CKD Severity
A prespecified FLOW analysis found no unexpected semaglutide safety pattern across baseline kidney-function groups, with important limits.
GLP-1 and GLP-2 in Mouse Intestinal Injury
A 2026 mouse study linked endogenous GLP-1 and GLP-2 signaling with protection from T cell-induced intestinal injury. It was not a human trial.
GLP-1 Response Differences in Three Trials
A reanalysis of three cardiovascular trials found only small covariate-explained differences in GLP-1 treatment response.
OAF Protein in a Mouse MASLD Model
A basic-research readout of OAF protein in high-fat-diet mice, including the SCPX mechanism and the limits on human interpretation.
Oral Semaglutide Kidney Outcomes in SOUL
SOUL found slower eGFR decline with oral semaglutide, but neither prespecified composite kidney outcome was significantly reduced.
Semaglutide Dose and Psychiatric Events
A retrospective semaglutide study linked higher attained doses with fewer later neuropsychiatric diagnoses, but it cannot establish protection or safety.
Semaglutide in Liver Organoids
A basic-research readout of semaglutide in a fatty-liver organoid model, with clear limits on what the laboratory findings can show.
Tirzepatide in a Real-World CKD Cohort
A 62-person kidney-clinic cohort found lower weight, HbA1c and albuminuria after tirzepatide initiation, with stable eGFR during short follow-up.
Blood Pressure Events in GLP-1 Trials
A 32-trial meta-analysis found different hypertension and hypotension signals for tirzepatide and semaglutide, without a direct pooled head-to-head test.
GLP-1s and shoulder replacement safety
A claims-database study found more 90-day readmissions among non-diabetic GLP-1 users after shoulder replacement, but it cannot establish cause.